Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Biomarcadores para diagnóstico de demencia

Resultados 61 resultados
LastUpdate Última actualización 15/03/2025 [07:49:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 25 a 50 de 61 nextPage  

ANTI-A-BETA PROTEIN ANTIBODIES, METHODS AND USES THEREOF

NºPublicación:  WO2025032070A1 13/02/2025
Solicitante: 
F HOFFMANN LA ROCHE AG [CH]
HOFFMANN LA ROCHE INC [US]
F. HOFFMANN-LA ROCHE AG,
HOFFMANN-LA ROCHE INC
WO_2025032070_A1

Resumen de: WO2025032070A1

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

Attenuated Total Reflectance-Based Biosensor for Conformation and Secondary Structure Analysis

NºPublicación:  US2025052675A1 13/02/2025
Solicitante: 
BETASENSE GMBH [DE]
betaSENSE GmbH
ES_2893322_T3

Resumen de: US2025052675A1

Provided herein is a biosensor for conformation and secondary structure analysis, notably for the direct non-invasive qualitative secondary structure analysis of a single selected protein within a complex mixture, as e.g. a body fluid, by vibrational spectroscopic methods. For the analysis it is not required that the selected substance be isolated, concentrated, or pretreated by a special preparative procedure.

ANTIBODIES TO AMYLOID BETA

NºPublicación:  US2025051428A1 13/02/2025
Solicitante: 
THE UNIV OF BRITISH COLUMBIA [CA]
PROMIS NEUROSCIENCES INC [CA]
The University of British Columbia,
ProMIS Neurosciences, Inc
CN_116333108_PA

Resumen de: US2025051428A1

The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.

COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING PHOSPHOLIPASE C ACTIVATOR AS AN ACTIVE INGREDIENT

NºPublicación:  US2025049741A1 13/02/2025
Solicitante: 
KOREA UNIV RESEARCH AND BUSINESS FOUNDATION [KR]
Korea University Research and Business Foundation
US_2023118869_PA

Resumen de: US2025049741A1

The present invention relates to a composition for preventing or treating Alzheimer's disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer's disease.

COMBINED DETECTION KIT FOR ASSISTING IN DIAGNOSIS OF ALZHEIMER'S DISEASE AND USE

NºPublicación:  WO2025030769A1 13/02/2025
Solicitante: 
ZHEJIANG GEWUZHIZHI BIOTECHNOLOGY CO LTD [CN]
\u6D59\u6C5F\u683C\u7269\u81F4\u77E5\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
WO_2025030769_PA

Resumen de: WO2025030769A1

The present invention relates to the technical field of biological medicines. Disclosed are a combined detection kit for assisting in diagnosis of Alzheimer's disease and the use. Disclosed is the combined use of at least four of amyloid β-proteins, phosphorylated Tau proteins, biomarkers of neurodegeneration or neuron damage, and biomarkers related to neuroimmune disorder, synaptic dysfunction and blood brain barrier alternation in assisting in diagnosis of Alzheimer's disease. Compared with single-biomarker detection existing in the market and the combined detection using a small number of markers disclosed in some published patents, the marker combined detection provided by the present invention achieves a higher specificity or sensitivity. The present invention establishes a brand-new algorithm model, and both AD scale rating and brain function imaging diagnosis result rating are incorporated into the algorithm model for cooperative diagnosis; under the condition of a 95% specificity, the diagnosis sensitivity thereof can reach 95%, which is far higher than that of similar products in the market.

COMBINED DETECTION KIT FOR DETECTING SEPSIS AND USE THEREOF

NºPublicación:  WO2025030768A1 13/02/2025
Solicitante: 
ZHEJIANG GEWUZHIZHI BIOTECHNOLOGY CO LTD [CN]
\u6D59\u6C5F\u683C\u7269\u81F4\u77E5\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
CN_116930510_PA

Resumen de: WO2025030768A1

A combined detection kit for detecting sepsis and the use thereof. The present invention relates to the use of a combination of at least two markers of CD14, CD95, HBP, HMGB-1, IFN-α, IFN-γ, IL-1β, IL-8, MIP-1β, MIF, PCT, TNF-α, sTREM-1, TLR-4 and TSP-1 in the detection of sepsis. The early diagnosis and screening of sepsis can be achieved by means of detecting relevant samples such as blood, urine, cerebrospinal fluid, feces, sputum or tissue fluid and combining algorithms to build a model, and bacterial infection, viral infection and sepsis can be distinguished. The combined detection kit has good diagnosis results in both the systemic inflammatory response stage and the compensatory anti-inflammatory response stage of sepsis; and under the condition of 98% specificity, the diagnosis sensitivity can reach 98%.

ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS

NºPublicación:  US2025049883A1 13/02/2025
Solicitante: 
THE CGP LAB LTD [NZ]
The CGP Lab Limited
AU_2025200383_A1

Resumen de: US2025049883A1

Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAX™ effectively improved the sensory function in patients with diabetic neuropathy.

A HUMAN IPSC-DERIVED MODEL FOR TAUOPATHIES

NºPublicación:  WO2025031900A1 13/02/2025
Solicitante: 
LUDWIG MAXIMILIANS UNIV MUENCHEN [DE]
LUDWIG-MAXIMILIANS-UNIVERSIT\u00C4T M\u00DCNCHEN
WO_2025031900_A1

Resumen de: WO2025031900A1

The present invention relates to a human ectoderm derived brain cell characterized by the following features: (1) the intron between exons 10 and 11 of the MAPT gene encoding the Tau protein has been removed by genome-editing from one or both allele(s); and (2) at least one of the alleles of the MAPT gene of (1) carries at least one mutation enhancing Tau aggregation and at least one mutation enhancing nucleation of Tau aggregation; or (3) one allele of the MAPT gene as defined in claim 1(1) carries at least one mutation enhancing Tau aggregation, preferably in exon 10, and the other allele carries at least one mutation enhancing nucleation of Tau aggregation, preferably in exon 11.

ANTI-A-BETA PROTEIN ANTIBODIES, METHODS AND USES THEREOF

NºPublicación:  US2025051429A1 13/02/2025
Solicitante: 
HOFFMANN LA ROCHE INC [US]
Hoffmann-La Roche Inc

Resumen de: US2025051429A1

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

試料中のタウタンパク質断片を検出する方法

NºPublicación:  JP2025504410A 12/02/2025
Solicitante: 
ジーティーインヴェントリミテッド
JP_2025504410_PA

Resumen de: AU2023207441A1

The invention relates to an

METHODS AND KITS FOR ASSESSING ALZHEIMER'S DISEASE

NºPublicación:  EP4505183A1 12/02/2025
Solicitante: 
MESO SCALE TECHNOLOGIES LLC [US]
MASSACHUSETTS GEN HOSPITAL [US]
Meso Scale Technologies, LLC,
The General Hospital Corporation
WO_2023196927_PA

Resumen de: WO2023196927A1

The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.

HIGH DOSE TREATMENTS FOR ALZHEIMER'S DISEASE

NºPublicación:  US2025042979A1 06/02/2025
Solicitante: 
GENENTECH INC [US]
GENENTECH, INC
US_2024076358_A1

Resumen de: US2025042979A1

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

DEORPHANIZING ODORS USING SINGLE CELL SEQUENCING

NºPublicación:  US2025043349A1 06/02/2025
Solicitante: 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
WO_2023102163_PA

Resumen de: US2025043349A1

Scents are perceived by the olfactory sensory neurons (OSNs) that line the upper nasal cavity. Each OSN expresses one odorant receptor, and these odorant receptors contact the scent molecules. Methods for determining which odorant receptor(s) are activated by a scent are lacking, making it difficult to replicate or improve scents. The technology as disclosed herein refers to methods relating to activating odor response genes found in olfactory sensory neurons after the neurons are exposed to at least one volatilized chemical compound.

ANTI-TAU MTBR ANTIBODIES AND METHODS TO DETECT CLEAVED FRAGMENTS OF TAU AND USES THEREOF

NºPublicación:  AU2023329330A1 06/02/2025
Solicitante: 
WASHINGTON UNIV
WASHINGTON UNIVERSITY
AU_2023329330_PA

Resumen de: AU2023329330A1

Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.

Animal, Fungal and Marine Sources of cGP and Increased cGP Concentration for Disease Management and for Treatment of Non-Neurological and/or Neurological Conditions

NºPublicación:  AU2025200383A1 06/02/2025
Solicitante: 
THE CGP LAB LTD
THE CGP LAB LIMITED
AU_2025200383_A1

Resumen de: AU2025200383A1

Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAXT for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAXTM effectively improved the sensory function in patients with diabetic neuropathy.

ポリペプチド分析のための組成物及び方法

NºPublicación:  JP2025503484A 04/02/2025
Solicitante: 
クアンタム-エスアイインコーポレイテッド
JP_2025503484_PA

Resumen de: CA3242558A1

Aspects of the application relate to methods and systems for obtaining information regarding multiple amino acids in a polypeptide based on binding interactions between the polypeptide and one or more amino acid recognizers. Kinetic signature information may be obtained from a series of signal pulses indicative of a series of binding events between one or more amino acid recognizers and an amino acid of a polypeptide (e.g., a terminal amino acid, an internal amino acid). The kinetic signature information (e.g., pulse duration, interpulse duration, recognition segment (RS) duration, intersegment duration) may be used to determine one or more chemical characteristics (e.g., identity, modification) of multiple amino acids of the polypeptide.

Methods for detecting b-isox precipitates or captured proteins as biofluid biomarkers

NºPublicación:  IL317512A 01/02/2025
Solicitante: 
YEEFAN MED INC [US]
WANG I FAN [TW]
CHANG HSIANG YU [TW]
TING CHEN HUNG [TW]
YEEFAN MED INC,
WANG I-Fan,
CHANG Hsiang-Yu,
TING Chen-Hung
IL_317512_A

Resumen de: AU2023294616A1

Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.

USE OF ADNF POLYPEPTIDES IN THERAPY

NºPublicación:  US2025032580A1 30/01/2025
Solicitante: 
RAMOT AT TEL AVIV UNIV LTD [IL]
RAMOT AT TEL-AVIV UNIVERSITY LTD
MX_2023011205_A

Resumen de: US2025032580A1

Uses of ADNF polypeptides in therapy are provided. Accordingly, there is provided a method of treating a disease associated with visual evoked potential impairment and/or speech impairment that is not due to vocal disturbance and in which the subject suffers from the visual evoked potential impairment and/or speech impairment, the method comprising administering to the subject a therapeutically effective amount of an ADNF polypeptide, wherein said ADNF polypeptide has a neurotrophic/neuroprotective activity in an in vitro cortical neuron culture assay.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER’S DISEASE

NºPublicación:  US2025032501A1 30/01/2025
Solicitante: 
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES [US]
SLOAN KETTERING INSTITUTE FOR CANCER RES [US]
Memorial Sloan-Kettering Cancer Center,
Memorial Hospital for Cancer and Allied Diseases,
Sloan-Kettering Institute for Cancer Research
WO_2023004054_PA

Resumen de: US2025032501A1

The present technology relates to methods for treating, preventing, and/or ameliorating Alzheimer's disease, in a subject in need thereof. In particular aspects, the present technology relates to the use of MAPK inhibitors to treat, prevent, and/or ameliorate Alzheimer's disease.

Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (PCpEV)

NºPublicación:  US2025032444A1 30/01/2025
Solicitante: 
EVEXYS BIOTECH OY [FI]
Evexys Biotech Oy
WO_2023099818_A1

Resumen de: US2025032444A1

The present invention is directed to 4-methylumbelliferone (hymecromone) or a derivative thereof for use in the treatment of major depressive disorder, mood disorders, anxiety-related disorders and depression associated with diseases or drug treatments including Alzheimer's disease, HIV associated neurocognitive disorders (HAND), psoriasis, chronic fatigue syndrome, Parkinson's disease, Long COVID syndrome and drug treatment regimens with IFN-alpha or vitamin A analogues, promoted by pathogenic extracellular vesicles, wherein 4-methylumbelliferone inhibits hyaluronic acid (HA) synthases and block the incorporation of HA and/or low molecular weight cleavage products into said extracellular vesicles. The present invention is also directed to a method for monitoring the efficacy of the treatment and delivery of therapeutic cargo to cells incorporating pEV by means of HA-binding receptors. The present invention further provides an in vitro screening method for identifying further inhibitors of HA synthases.

COMPOSITIONS, METHODS AND USES FOR EXOSOME-ASSOCIATED BIOMARKERS FOR EARLY DIAGNOSIS AND TREATMENT OF HEALTH CONDITIONS

NºPublicación:  WO2025024817A1 30/01/2025
Solicitante: 
THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE [US]
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
WO_2025024817_PA

Resumen de: WO2025024817A1

Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.

KIT OR DEVICE AND METHOD FOR DETECTING DEMENTIA

NºPublicación:  EP4498086A2 29/01/2025
Solicitante: 
TORAY INDUSTRIES [JP]
NAT CT GERIATRICS & GERONTOLOGY [JP]
Toray Industries, Inc,
National Center for Geriatrics and Gerontology
EP_4498086_A2

Resumen de: EP4498086A2

An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.

Métodos de tratamiento usando nivel de p-tau181.

NºPublicación:  CL2024002309A1 24/01/2025
Solicitante: 
EISAI R&D MAN CO LTD [JP]
EISAI R&D MANAGEMENT CO., LTD
MX_2024009492_A

Resumen de: MX2024009492A

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

METHOD FOR DETECTING NEURODEGENERATIVE DISEASE USING SHORT-CHAIN RNA

NºPublicación:  US2025027140A1 23/01/2025
Solicitante: 
TORAY INDUSTRIES [JP]
TORAY INDUSTRIES, INC
US_2025027140_PA

Resumen de: US2025027140A1

Disclosed is a method that enables detection of whether or not a subject is affected by a neurodegenerative disease, which method is simpler and more effective than conventional methods. This method includes the steps of: (a) preparing an extracellular vesicle fraction from a body fluid sample of the subject; (b) counting the number of extracellular vesicles contained in the extracellular vesicle fraction obtained in Step (a), to obtain the number of the extracellular vesicles; (c) measuring the total amount of short-chain RNA contained in all extracellular vesicles counted in Step (b), to obtain the total amount of short-chain RNA per extracellular vesicle; and (d) judging the subject as being affected by the neurodegenerative disease in a case where the total amount of short-chain RNA per extracellular vesicle obtained in Step (c) is larger than a total amount of short-chain RNA per extracellular vesicle obtained from a body fluid sample of a healthy individual.

P-TAU IMMUNOASSAY

Nº publicación: WO2025018933A1 23/01/2025

Solicitante:

MONTOLIU GAYA LAIA [SE]
LANTERO RODRIGUEZ JUAN [SE]
BLENNOW KAJ [SE]
MONTOLIU GAYA, Laia,
LANTERO RODRIGUEZ, Juan,
BLENNOW, Kaj

WO_2025018933_PA

Resumen de: WO2025018933A1

The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.

traducir